Close menu




May 1st, 2025 | 07:10 CEST

A bombshell at Nel ASA! Buying opportunity for Bayer and Defence Therapeutics shares?

  • Biotechnology
  • Biotech
  • renewableenergies
  • Pharma
Photo credits: Bayer AG

A bombshell at Nel ASA. The hydrogen specialist has reported its first quarter results: revenue and order intake are down, while the Company is sliding deep into the red. Will new major shareholder Samsung bring about a turnaround? Defence Therapeutics is a hot rebound candidate with takeover speculation. The biotech company is consistently pushing ahead with the monetization of its technology and has found a strong partner. The decline in the share price in recent months offers opportunities. A lot of negative news is certainly already priced into Bayer's share price, but is that enough to buy the stock? Yes, according to analysts.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: NEL ASA NK-_20 | NO0010081235 , BAYER AG NA O.N. | DE000BAY0017 , DEFENCE THERAPEUTICS INC | CA24463V1013

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Defence Therapeutics: Stock with catch-up potential and takeover speculation

    Defence Therapeutics currently offers an interesting entry opportunity. In February, the biotech company's share price was still above EUR 1 – it is currently EUR 0.48. The Company is making great strides in drug development and aims to generate additional revenue by licensing out its own platform. There is also takeover speculation.

    Defence Therapeutics is working on new vaccines against cancer. The Company relies on its proprietary Accum® technology, which enables the precise delivery of vaccine antigens or ADCs in their intact form to the target cells. The ARM-002 vaccine is currently being tested in difficult-to-treat cancers such as pancreatic, colon, and ovarian cancer.

    Most recently, the Company announced an important partnership with Canadian Nuclear Laboratories ("CNL"). Canada's leading nuclear research facility will conduct preclinical studies combining actinium-225 ("Ac-225") alpha particle radiation therapy with Defence's Accum® delivery technology. The synergy between Accum® and CNL is expected to advance precision oncology and lead to more effective and safer treatments.

    The results of Ac-225 in targeted radiation therapies for cancer treatment are very promising. Ac-225 emits powerful alpha particles that irreparably damage the DNA of cancer cells, leading to cell death. The partners now want to test various antibodies modified with Accum® technology to find the variant that can best penetrate the cell nucleus. The goal is to maintain the therapeutic efficacy of Ac-225 while reducing the required dosage and thus minimizing side effects. The partners are thus addressing a huge market. According to straitsresearch.com, the global radiopharmaceutical market is expected to reach a volume of USD 16.87 billion by 2033.

    Nel ASA: Weak quarterly figures

    Unlike Defence Therapeutics, Nel ASA has little positive news to report. Yesterday, Nel reported its results for the first quarter of 2025. The Company had to cope with a 44% decline in net sales (revenue from customer contracts) to NOK 155 million. The Norwegian company slipped back into the red in terms of operating earnings (EBITDA). The loss amounted to NOK -115 million. In the same quarter of the previous year, a positive EBITDA of NOK 32 million was achieved. The temporary production stoppage in the Alkaline division contributed to the negative development. The net loss amounted to NOK -179 million (Q1 2024: NOK 39 million).

    Order intake came in at NOK 311 million, around 22% below the same quarter last year. At the end of the quarter, the order backlog amounted to NOK 1,460 million. This was 10% less than at the end of 2024 and 31% less than in the first quarter of 2024. Nevertheless, Nel still had NOK 2.1 billion in cash at the end of March.

    Nel CEO Håkon Volldal remains optimistic about the future: "With a solid cash position, proven production capacity, and a portfolio of groundbreaking technologies in development, we are uniquely positioned in the market. The continued interest of leading strategic and industrial investors, such as SAMSUNG E&A, clearly confirms the Company's long-term potential." Samsung's entry currently seems to be the only ray of hope. Nel shares reacted little to the news and were trading virtually unchanged at NOK 2.276 yesterday afternoon.

    Bayer: mwb research recommends buying after AGM

    Bayer shareholders have not had much to cheer about for a long time. The share price has been on a downward trend for around 10 years now. The mood at the annual general meeting at the end of last week was correspondingly subdued. The analysts at mwb research subsequently published a detailed update.

    According to this, Bayer confirmed that 2025 would be the most challenging year of the planned turnaround, with expected stagnating consolidated revenue year-on-year and a decline in profit and free cash flow. Due to the patent expiry for Xarelto, net sales in the pharmaceuticals division will be slightly below those of 2024, and margins will be under pressure. The Consumer Health division aims to grow as fast as the market and keep EBITDA margins stable. Crop Science remains the most challenging segment, with sales expected to decline in the first quarter of 2025 and margins under pressure for the full year. Overall, Bayer reaffirmed its medium-term revenue growth targets of more than EUR 3.5 billion and an increase in the EBITDA margin to the mid-20% range by 2029. However, 2025 will be a challenging year.

    The biggest issue for Bayer remains litigation in the US. Ongoing court proceedings and negative rulings relating to glyphosate are weighing on the Company. In March 2025, Bayer filed a petition with the US Supreme Court, which could be a potential turning point if accepted. From mwb's perspective, credible progress in settling litigation over the next 12 months would be an important catalyst for a revaluation of the stock, which currently prices in a very negative scenario.

    Since much of the negative news is already priced in, analysts recommend buying Bayer shares. The target price is EUR 29. The share is currently trading at just over EUR 23.


    Defence Therapeutics shares appear ripe for a rebound at present. The decline in the share price in recent months is not attributable to the Company's operating performance. Takeover speculation is keeping the price down and could lead to a positive surprise. At Nel, revenue, earnings, and order intake are declining, so there is no urgent need to buy at present. This also applies to Bayer. Although the share price appears to reflect many negative factors, negative news about glyphosate could emerge at any time.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Fabian Lorenz on October 22nd, 2025 | 07:30 CEST

    SHARE PRICE EXPLOSION for commodity gems!? Nordex, Aurubis, Salzgitter, and Power Metallic Mines!

    • Mining
    • Lithium
    • Copper
    • Commodities
    • Steel
    • Wind
    • renewableenergies

    Shares in the commodities and precious metals sector have been unstoppable in recent weeks. Power Metallic Mines could soon become an explosive latecomer to the rally. There are good reasons for this, as the CEO recently made clear. At Aurubis, the rally appears to be over for now. Analysts are skeptical, and the major shareholder is cashing in his shares - albeit in an unusual way. So should you sell now, too? The past few months have been unusually positive for Nordex. There is currently no sign of a slump in the wind business. What are analysts saying after the latest order intake?

    Read

    Commented by Fabian Lorenz on October 22nd, 2025 | 07:15 CEST

    HYDROGEN IS ALIVE! Bloom Energy, thyssenkrupp nucera, and dynaCERT! 1,000% not enough?

    • Hydrogen
    • greenhydrogen
    • cleantech
    • renewableenergies

    Plug Power has gained nearly 500% since May, proving that hydrogen is very much alive. The applications may be different from what was expected in the hype a few years ago - more specific and niche-focused. Investors are speculating that hydrogen will benefit from the energy boom driven by artificial intelligence. The same applies to Bloom Energy, whose stock has exploded by 1,000% over the past year. dynaCERT is active in an exciting niche, offering conversion kits for diesel engines ranging from trucks to container ships. Initial sales successes give hope for more. Will emission certificates follow? And what is Germany's hydrogen hope, thyssenkrupp nucera, doing? It remains in the shadow of TKMS. Still, one analyst sees upside potential of around 50%.

    Read

    Commented by Nico Popp on October 22nd, 2025 | 07:00 CEST

    Important piece of the puzzle in the fight against cancer: Vidac Pharma, Roche, Merck & Co.

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer
    • Technology
    • Innovations

    The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around USD 300 billion. However, there is no single approach. Instead, new modalities and technologies such as antibody-drug conjugates (ADCs), cell and gene therapies, and radiopharmaceuticals are transforming the industry and gaining significant traction. One thing is clear: progress in the biotech sector is increasingly achieved through the combination of active ingredients and technologies. What role does the biotech company Vidac Pharma play in this?

    Read